Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1359-1371

  Bernal, Monica ^a   Ruiz Cabello, Francisco ^a,b   Concha, Angel ^a   Paschen, Annette ^c   Garrido, Federico ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

2 microglobulin; HLA class I; Human leukocyte antigen; Loss of heterozygosity; Microsatellite instability; Tumor immune escape

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ADENOVIRUS VECTOR; BETA 2 MICROGLOBULIN; DNA; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; RECOMBINANT PROTEIN;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; B2M GENE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNODEFICIENCY; CHROMOSOME 15; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FIBROSARCOMA; FRAMESHIFT MUTATION; GENE; GENE FUNCTION; GENE LOSS; GENE TARGETING; GENETIC STABILITY; HETEROZYGOSITY LOSS; HIGH MICROSATELLITE STABILITY; HUMAN; IN VIVO STUDY; INDEL MUTATION; MELANOMA; METASTASIS; MICROSATELLITE MARKER; MICROSATELLITE STABILITY; NONHUMAN; NUCLEOTIDE MOTIF; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TUMOR ESCAPE; TUMOR REJECTION; VIRAL GENE DELIVERY SYSTEM;

BETA 2-MICROGLOBULIN; COLORECTAL NEOPLASMS; FRAMESHIFT MUTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MELANOMA; MICROSATELLITE INSTABILITY; PHENOTYPE; TUMOR ESCAPE;

EID: 84866535863     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1321-6     Document Type: Review

References (75)

1. Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 188:33-42 (Pubitemid 35398863)
2. Wang E, Worschech A, Marincola FM (2008) The immunologic constant of rejection. Trends Immunol 29:256-262
3. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95 (Pubitemid 27107103)
4. del Campo Ana B, Carretero J, Aptsiauri N, Garrido F (2012) Targeting tumor HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79:147-154
5. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M (1983) The b2m mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 2:239-243
6. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520-529 (Pubitemid 29002755)
7. Pérez B, Benitez R, Fernández MA, Oliva MR, Soto JL, Serrano S, López Nevot MA, Garrido F (1999) A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569-572 (Pubitemid 29257768)
8. Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759-767 (Pubitemid 36110232)
9. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S (1991) Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284-292
10. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W (1996) Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 47:364-371 (Pubitemid 26168341)
11. Maleno I, Aptsiauri N, Cabrera T, Gallego A, Paschen A, López-Nevot MA, Garrido F (2011) Frequent loss of heterozygosity in the b2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 63:65-71
12. Romero JM, Jiménez P, Cabrera T, Cózar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/b2m complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 113:605-610 (Pubitemid 40038737)
13. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681-686
14. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 6:1695-1697 (Pubitemid 27050239)
15. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561 (Pubitemid 23186645)
16. Umar A, Kunkel TA (1996) DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238:297-307 (Pubitemid 26188243)
17. Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673-680 (Pubitemid 351494153)
18. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J (1997) Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 57:4749-4756 (Pubitemid 27468981)
19. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257 (Pubitemid 28521189)
20. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875 (Pubitemid 28278073)
21. Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler KW, Vogelstein B, Peltomäki P, Kolodner RD, Nilbert M, Lindblom A (2007) Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 99:291-299 (Pubitemid 47073492)
22. Speicher MR (1995) Microsatellite instability in human cancer. Oncol Res 7:267-275
23. Bichara M, Pinet I, Schumacher S, Fuchs RP (2000) Mechanisms of dinucleotide repeat instability in Escherichia coli. Genetics 154:533-542 (Pubitemid 30096578)
24. Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, Schwitalle Y, Kuchenbuch B, von Knebel Doeberitz M (2007) Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 121:454-458 (Pubitemid 46917717)
25. Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: b2m inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSInegative tumors. Tissue Antigens 6:211-219 (Pubitemid 36605543)
26. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S (1998) Beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 101:2720-2729 (Pubitemid 28294581)
27. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462-1471
28. Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, Pang ST, Hasumi K, Ferrone S, Liao SK (2009) Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding b2m genes. Cancer Immunol Immunother 58:395-408
29. Jordanova ES, Riemersma SA, Philippo K, Schuuring E, Kluin PM (2003) Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 103:393-398 (Pubitemid 36076433)
30. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961-976
31. Tomlinson IP, Beck NE, Bodmer WF (1996) Allele loss on chromosome 11q and microsatellite instability in malignant melanoma. Eur J Cancer 32:1797-1802 (Pubitemid 26306895)
32. Birindelli S, Tragni G, Bartoli C, Ranzani GN, Rilke F, Pierotti MA, Pilotti S (2000) Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 86:255-261 (Pubitemid 30180822)
33. Hussein MR, Sun M, Tuthill RJ, Roggero E, Monti JA, Sudilovsky EC, Wood GS, Sudilovsky O (2001) Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 28:343-350 (Pubitemid 32667004)
34. Palmieri G, Ascierto PA, Cossu A, Colombino M, Casula M, Botti G, Lissia A, Tanda F, Castello G (2003) Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 13:167-170 (Pubitemid 36583979)
35. Hussein MR (2004) Genetic pathways to melanoma tumorigenesis. J Clin Pathol 57:797-801 (Pubitemid 39061426)
36. Bicknell DC, Rowant A, Bodmer WF (1994) b2-Microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 91:4751-4755
37. Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D (2006) The coincidence of chromosome 15 aberrations and b2m gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 12:3297-3305
38. Di Noia J, Neuberger M (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76:1-22
39. Kim CJ, Song JH, Cho YG, Cao Z, Kim SY, Nam SW, Lee JY, Park WS (2007) Activation-induced cytidine deaminase expression in gastric cancer. Tumour Biol 28:333-339 (Pubitemid 351567551)
40. Marusawa H, Aberrant AID (2008) Expression and human cancer development. Int J Biochem Cell Biol 40:1399-1402
41. Shivarov V, Shinkura R, Doi T, Begum NA, Nagaoka H, Okazaki IM, Ito S, Nonaka T, Kinoshita K, Honjo T (2009) Molecular mechanism for generation of antibody memory. Philos Trans R Soc Lond B Biol Sci 364:569-575
42. Del Campo A, Mendez R, Carretero J, Maleno I, Zinchenko S, Ruiz-Cabello F, Kyte JA, Aamdal S, Gaudernak G, Aptsiauri N, Garrido F (2010) Analysis of HLA class I expression in metastatic lesions obtained from a melanoma patient before and after treatment with tumor-mRNA-transfected DCs: immunoselection of cells with beta 2-microglobulin gene alterations. Tissue Antigens 75:488
43. Marusawa H, Aberrant AID (2008) Expression and human cancer development. Int J Biochem Cell Biol 40:1399-1402
44. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439-447
45. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T (2012) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 131:387-395
46. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521-527 (Pubitemid 36966208)
47. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109-119
48. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418-6424 (Pubitemid 40994430)
49. Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51-81 (Pubitemid 43765799)
50. Garrido F, Cabrera T, Aptsiauri N (2010) ''Hard'' and ''soft'' lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249-256
51. Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249-276
52. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer 94:243-251 (Pubitemid 32911420)
53. Rodriguez T, Mendez R, del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34
54. Khan AN, Gregorie CJ (2008) Tomasi TB Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57:647-654
55. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100
56. Carretero R, Cabrera T, Gil H, Saenz-Lopez P, Maleno I, Aptsiauri N, Cozar JM, Garrido F (2011) Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 129:839-846
57. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P (2010) SelTarbase, a database of human mononucleotide microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 38 (Database issue):D682-D689
58. Yamamoto H, Sawai H, Perucho M (1997) Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 57:4420-4426 (Pubitemid 27413454)
59. del Campo AB, Aptsiauri N, Mendez R, Zinchenko S, Vales A, Paschen A, Ward S, Ruiz-Cabello F, Gonzalez-Aseguinolaza G, Garrido F (2009) Efficient recovery of HLA class I expression in human tumor cells after b2m gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol 70:125-135
60. Perez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Klein G, Karre K, Garrido F (1990) A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46:258-261 (Pubitemid 20252086)
61. Garrido ML, Perez M, Delgado C, Rojano J, Algarra I, Garrido A, Garrido F (1986) Immunogenicity of H-2 positive and H-2 negative clones of a mouse tumour, GR9. J Immunogenet 13:159-167 (Pubitemid 17001676)
62. Jager MJ, Hurks HM, Levitskaya J, Kiessling R (2002) HLA expression in uveal melanoma:there is no rule without some exception. Human Immunol 63:444-451 (Pubitemid 34620079)
63. Ma D, Luyten GP, Luider TM, Niederkorn JY (1994) Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 36:435-441
64. Tikidzhieva A, Benner A, Michel S, Formentini A, Link K-H, Dippold W, von Knebel Doeberitz M, Kornmann M, Kloor M (2012) Microsatellite instability and beta2-microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 106:1239-1245
65. Watson NF, Madjd Z, Splendlove I, Ellis IO, Scholefield JH, Durant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with poor prognosis. Int J Cancer 118:6-10 (Pubitemid 41681574)
66. Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW (2011) b2-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 71:2600-2610
67. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC, Chung LW (2006) beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66:9108-9116 (Pubitemid 44521130)
68. Huang WC, Zhau HE, Chung LW (2010) Androgen receptor survival signalling is blocked by anti-{beta}2-microglobulin monoclonal antibody via a mitogen-activated protein kinase/lipogenic pathway in human prostate cancer cells. J Biol Chem 285:7947-7956
69. Chen H, Gabrilovich D, Virmanii A, Ratnani I, Girgis K, Nadaf-Rahrovm S, Fernandez-Viña M, Carbone P (1996) Structural and functional analysis of b2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 67:756-763 (Pubitemid 26348802)
70. De Miranda NF, Nielsen M, Pereira D, van Puijenbroek M, Vasen HF, Hes FJ, van Wezel T, Morreau H (2009) MUTYH-associated polyposis carcinomas frequently lose HLA class I expression-a common event amongst DNA-repair-deficient colorectal cancers. J Pathol 219:69-76
71. Bernal M, Concha A, Sáenz-López P, Rodríguez AI, Cabrera T, Garrido F, Ruiz-Cabello F (2011) Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother 60:869-882
72. Gattoni-Celli S, Kirsch K, Timpane R, Isselbacher KJ (1992) Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Res 52:1201-1204
73. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S (1993) Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 91:684-692 (Pubitemid 23064155)
74. Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel b2m loss-of-function in melanoma cells. J Biol Chem 281:18763-18773 (Pubitemid 44035537)
75. Baba T, Hanagiri T, Ichiki Y, Kuroda K, Shigematsu Y, Mizukami M, Sugaya M, Takenoyama M, Sugio K, Yasumoto K (2007) Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 98:1795-1802 (Pubitemid 47487918)